These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 9875449)

  • 1. Resistance mechanism of Acinetobacter spp. strains resistant to DW-116, a new quinolone.
    Choi KH; Baek MC; Kim BK; Choi EC
    Arch Pharm Res; 1998 Jun; 21(3):310-4. PubMed ID: 9875449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ciprofloxacin and the fluoroquinolones. New concepts on the mechanism of action and resistance.
    Fisher LM; Lawrence JM; Josty IC; Hopewell R; Margerrison EE; Cullen ME
    Am J Med; 1989 Nov; 87(5A):2S-8S. PubMed ID: 2574005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of distinct ciprofloxacin susceptibility in Acinetobacter spp. by detection of the gyrA gene mutation using real-time PCR.
    Sheng WH; Lin YC; Wang JT; Chen YC; Chang SC; Hsia KC; Wu RJ; Li SY
    Mol Cell Probes; 2009; 23(3-4):154-6. PubMed ID: 19281841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation in the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumannii.
    Vila J; Ruiz J; Goñi P; Marcos A; Jimenez de Anta T
    Antimicrob Agents Chemother; 1995 May; 39(5):1201-3. PubMed ID: 7625818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of high-level quinolone resistance in Campylobacter jejuni.
    Gootz TD; Martin BA
    Antimicrob Agents Chemother; 1991 May; 35(5):840-5. PubMed ID: 1649570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Substitutions of Ser83Leu in GyrA and Ser80Leu in ParC Associated with Quinolone Resistance in Acinetobacter pittii.
    Gu DX; Hu YJ; Zhou HW; Zhang R; Chen GX
    Microb Drug Resist; 2015 Jun; 21(3):345-51. PubMed ID: 25514581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of mutations in DNA gyrase genes on quinolone resistance in Campylobacter jejuni.
    Changkwanyeun R; Yamaguchi T; Kongsoi S; Changkaew K; Yokoyama K; Kim H; Suthienkul O; Usui M; Tamura Y; Nakajima C; Suzuki Y
    Drug Test Anal; 2016 Oct; 8(10):1071-1076. PubMed ID: 26857529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amino acid substitutions of quinolone resistance determining regions in GyrA and ParC associated with quinolone resistance in Acinetobacter baumannii and Acinetobacter genomic species 13TU.
    Liu YH; Kuo SC; Lee YT; Chang IC; Yang SP; Chen TL; Fung CP
    J Microbiol Immunol Infect; 2012 Apr; 45(2):108-12. PubMed ID: 22153765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterisation of DNA gyrase and measurement of drug accumulation in clinical isolates of Acinetobacter baumannii resistant to fluoroquinolones.
    Moreau NJ; Houot S; Joly-Guillou ML; Bergogne-Bérézin E
    J Antimicrob Chemother; 1996 Dec; 38(6):1079-83. PubMed ID: 9023657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-nucleotide polymorphism mutation spectra and resistance to quinolones in Salmonella enterica serovar Enteritidis with a mutator phenotype.
    Levy DD; Sharma B; Cebula TA
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2355-63. PubMed ID: 15215081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
    Ferrero L; Cameron B; Manse B; Lagneaux D; Crouzet J; Famechon A; Blanche F
    Mol Microbiol; 1994 Aug; 13(4):641-53. PubMed ID: 7997176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance.
    Akasaka T; Tanaka M; Yamaguchi A; Sato K
    Antimicrob Agents Chemother; 2001 Aug; 45(8):2263-8. PubMed ID: 11451683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones.
    Strahilevitz J; Robicsek A; Hooper DC
    Antimicrob Agents Chemother; 2006 Feb; 50(2):600-6. PubMed ID: 16436716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.
    Strahilevitz J; Hooper DC
    Antimicrob Agents Chemother; 2005 May; 49(5):1949-56. PubMed ID: 15855518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection and genetic characterization of Streptococcus pneumoniae mutants resistant to the des-F(6) quinolone BMS-284756.
    Hartman-Neumann S; DenBleyker K; Pelosi LA; Lawrence LE; Barrett JF; Dougherty TJ
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2865-70. PubMed ID: 11557482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of mutations in the gyrA and parC genes in quinolone-resistant clinical isolates of Enterobacter cloacae.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Nishino Y; Ishihara S; Kawada Y
    J Antimicrob Chemother; 1997 Oct; 40(4):543-9. PubMed ID: 9372424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of quinolone susceptibility in Campylobacter jejuni associated with different gyrA mutations.
    McIver C; Hogan T; White P; Tapsall J
    Pathology; 2004 Apr; 36(2):166-9. PubMed ID: 15203753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence and mechanisms of quinolone resistance among selected nontyphoid Salmonella isolated from food animals and humans in Korea.
    Tamang MD; Nam HM; Kim A; Lee HS; Kim TS; Kim MJ; Jang GC; Jung SC; Lim SK
    Foodborne Pathog Dis; 2011 Nov; 8(11):1199-206. PubMed ID: 21877929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quinolone-resistance mutations in the topoisomerase IV parC gene of Acinetobacter baumannii.
    Vila J; Ruiz J; Goñi P; Jimenez de Anta T
    J Antimicrob Chemother; 1997 Jun; 39(6):757-62. PubMed ID: 9222045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lomefloxacin (SC 47111 or NY-198), a new difluorinated quinolone: comparison of the in vitro activity with other broad spectrum antimicrobials against Enterobacteriaceae, Acinetobacter spp, Aeromonas spp, and Pseudomonas aeruginosa.
    Aldridge KE; Henderberg A; Sanders CV
    Diagn Microbiol Infect Dis; 1989; 12(3 Suppl):1S-6S. PubMed ID: 2507219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.